Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FRA:GU5's 5-Year Yield-on-Cost % is ranked better than 81.16% of 69
companies
in the Medical Distribution industry
Industry Median: 3.09
vs FRA:GU5: 10.68
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Guangzhou Baiyunshan Pharmaceutical Holdings Co 5-Year Yield-on-Cost % Related Terms
FRA:GU5 vs MCK, COR, CAH: 5-Year Yield-on-Cost % Comparison
For the Medical Distribution subindustry, Guangzhou Baiyunshan Pharmaceutical Holdings Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Baiyunshan Pharmaceutical Holdings Co 5-Year Yield-on-Cost % vs Medical Distribution Industry
Guangzhou Baiyunshan Pharmaceutical Holdings Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) has a 5-Year Yield-on-Cost % of 10.68 as of Jul. 29, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. This is 203% above median its historical median of 3.53. Over the past decade, Guangzhou Baiyunshan Pharmaceutical Holdings Co's 5-Year Yield-on-Cost % has ranged from 1.13 to 10.80. According to the industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #13 out of 69 companies in the Medical Distribution industry, placing it in the top 18.8%.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's 5-Year Yield-on-Cost % too high?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current 5-Year Yield-on-Cost % of 10.68 is 203% above median its 10-year median of 3.53. Over the past 10 years, this metric has ranged from a low of 1.13 to a high of 10.80. The Medical Distribution industry median 5-Year Yield-on-Cost % is 3.09. Guangzhou Baiyunshan Pharmaceutical Holdings Co's value of 10.68 is 245.6% above this industry median. Based on the distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #13 out of 69 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's 5-Year Yield-on-Cost % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #13 out of 69 companies for 5-Year Yield-on-Cost %. This places Guangzhou Baiyunshan Pharmaceutical Holdings Co in the top 19% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 3.09. Guangzhou Baiyunshan Pharmaceutical Holdings Co's value of 10.68 is 245.6% above this benchmark. Historically, Guangzhou Baiyunshan Pharmaceutical Holdings Co's own 5-Year Yield-on-Cost % has ranged from 1.13 to 10.80 over the past decade. While the company's 10-year median is 3.53 vs. the industry median of 3.09, Guangzhou Baiyunshan Pharmaceutical Holdings Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Distribution company?
The median 5-Year Yield-on-Cost % among Medical Distribution companies is 3.09, based on 69 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current 5-Year Yield-on-Cost % of 10.68 is 245.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. For the Medical Distribution industry, the median 5-Year Yield-on-Cost % is 3.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current 5-Year Yield-on-Cost % is 10.68, which is 203% above median its own 10-year median of 3.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.40, compared to a current price of €1.72 — trading 28.3% below its estimated fair value. The current 5-Year Yield-on-Cost % is 10.68, which is 203% above median its 10-year median of 3.53 and 245.6% above the Medical Distribution industry median of 3.09. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5), the current 5-Year Yield-on-Cost % is 10.68 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued.
The current stock price of €1.72 is trading 28.3% below its estimated GF Value™ of €2.40.
GuruFocus considers Guangzhou Baiyunshan Pharmaceutical Holdings Co to be Modestly Undervalued.
Key valuation signals for FRA:GU5:
5-Year Yield-on-Cost %: 10.68 (203% above median its 10-year median of 3.53)
GF Value™: €2.40 vs. price of €1.72 (28.3% below fair value)
Industry Position: 245.6% above the Medical Distribution median (#13 of 69)
No single metric tells the full story. See the FRA:GU5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Business Description
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.
74GF Score
Get the complete analysis for FRA:GU5
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GU5 has been successfully added to your 
